John Roberts, exiting Vyant Bio CEO
February 3, 2023 10:17 AM ESTUpdated 10:50 AM
People

Neu­rode­gen­er­a­tive biotech Vyant warns of po­ten­tial wind-down

Kyle LaHucik

Senior Reporter

The CEO and chief sci­en­tif­ic of­fi­cer of Vyant Bio are out the door as the lit­tle-known but pub­licly-list­ed neu­rode­gen­er­a­tive biotech search­es for an ex­it or …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times